1219737-12-8

Basic information

• Product Name: 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid
• Synonyms: 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid
• CAS NO: 1219737-12-8
• Molecular Weight: 454.912
• Mol File: 1219737-12-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 712.6±70.0 °C(Predicted)
• Density: 1.349±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid(1219737-12-8)
• EPA Substance Registry System: 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid(1219737-12-8)

Safety Data

• Hazardous Substances Data: 1219737-12-8(Hazardous Substances Data)

Usage

Uses

MK-3903 is a potent and selective AMP-activated protein kinase (AMPK) activator with an EC50 of 8 nM.

Upstream product

• 1219741-21-5 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione 
• 1219741-56-6 5-biphenyl-4-yl-6-chloro-2-(methylsulfonyl)-1H-benzimidazole 
• 1219741-22-6 6-chloro-5-iodo-2-(methylthio)-1H-benzimidazole 
• 1219741-19-1 6-chloro-5-iodo-2-(methylsulfonyl)-1H-benzo[d]imidazole 
• 1219741-21-5 3,5-chloro-6-iodo-1,3-dihydro-2H-benzimidazole-2-thione 
• 1219741-20-4 2, 4-chloro-5-iodobenzene-1,2-diamine 
• 335349-57-0 2-nitro-4-iodo-5-chloroaniline 
• 1635-61-6 5-chloro-2-nitroaniline 
• 1219741-57-7 methyl 5-[(5-biphenyl-4-yl-6-chloro-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 

Relevant articles and documents

Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase

5′-Adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of mammalian energy homeostasis and has been implicated in mediating many of the beneficial effects of exercise and weight loss including lipid and glucose trafficking. As such,

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.